Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Paediatric Haematology-Oncology Department and "Tettamanti" Research Centre, Milano-Bicocca University, "Fondazione MBBM", San Gerardo Hospital, Monza, Italy.
Veronica
V
Leoni
Paediatric Haematology-Oncology Department and "Tettamanti" Research Centre, Milano-Bicocca University, "Fondazione MBBM", San Gerardo Hospital, Monza, Italy abiondi.unimib@gmail.com.
Andrea
A
Biondi
D000328:Adult; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D018365:Neoplasm, Residual; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D016019:Survival Analysis
D018033:Antibodies, Bispecific; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C510808:blinatumomab; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl